WO2021136404A1 - 一种治疗Usher综合征的方法和其组合物 - Google Patents
一种治疗Usher综合征的方法和其组合物 Download PDFInfo
- Publication number
- WO2021136404A1 WO2021136404A1 PCT/CN2020/141501 CN2020141501W WO2021136404A1 WO 2021136404 A1 WO2021136404 A1 WO 2021136404A1 CN 2020141501 W CN2020141501 W CN 2020141501W WO 2021136404 A1 WO2021136404 A1 WO 2021136404A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- arrna
- rna
- target
- editing
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- 208000014769 Usher Syndromes Diseases 0.000 title abstract description 25
- 239000000203 mixture Substances 0.000 title description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 121
- 230000035772 mutation Effects 0.000 claims abstract description 65
- 238000005516 engineering process Methods 0.000 claims abstract description 49
- 101100428002 Homo sapiens USH2A gene Proteins 0.000 claims abstract description 30
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims abstract description 22
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims abstract description 14
- 102000055025 Adenosine deaminases Human genes 0.000 claims abstract description 14
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims abstract description 11
- 229960005305 adenosine Drugs 0.000 claims abstract description 11
- 108020004394 Complementary RNA Proteins 0.000 claims abstract description 5
- 239000003184 complementary RNA Substances 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 120
- 150000007523 nucleic acids Chemical class 0.000 claims description 50
- 102220000929 rs111033364 Human genes 0.000 claims description 49
- 102000039446 nucleic acids Human genes 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 241000702421 Dependoparvovirus Species 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 19
- 241001634120 Adeno-associated virus - 5 Species 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 18
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 16
- 102100037930 Usherin Human genes 0.000 claims description 15
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 14
- 239000013612 plasmid Substances 0.000 claims description 13
- 239000013607 AAV vector Substances 0.000 claims description 12
- 239000002502 liposome Substances 0.000 claims description 12
- 150000002632 lipids Chemical class 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 9
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 101000805941 Homo sapiens Usherin Proteins 0.000 claims description 8
- 241000713666 Lentivirus Species 0.000 claims description 7
- 210000000234 capsid Anatomy 0.000 claims description 7
- 208000015181 infectious disease Diseases 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000001328 optic nerve Anatomy 0.000 claims description 4
- 210000000860 cochlear nerve Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 11
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 description 31
- 108090000623 proteins and genes Proteins 0.000 description 28
- 239000005090 green fluorescent protein Substances 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 22
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 101710138401 Usherin Proteins 0.000 description 14
- 210000001508 eye Anatomy 0.000 description 14
- 230000014616 translation Effects 0.000 description 14
- 108091026890 Coding region Proteins 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 238000012163 sequencing technique Methods 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 238000010357 RNA editing Methods 0.000 description 10
- 230000026279 RNA modification Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 9
- 229920002521 macromolecule Polymers 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- 206010064571 Gene mutation Diseases 0.000 description 8
- 108020005004 Guide RNA Proteins 0.000 description 8
- 101710163270 Nuclease Proteins 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 7
- 230000004393 visual impairment Effects 0.000 description 7
- 101150063416 add gene Proteins 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 238000010839 reverse transcription Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091005461 Nucleic proteins Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 208000018769 loss of vision Diseases 0.000 description 4
- 231100000864 loss of vision Toxicity 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 3
- 206010011882 Deafness congenital Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 101100428003 Mus musculus Ush2A gene Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000001808 exosome Anatomy 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 210000003786 sclera Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 208000001140 Night Blindness Diseases 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 230000009948 RNA mutation Effects 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical class C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- -1 double-stranded DNA Chemical class 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 238000010362 genome editing Methods 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000036438 mutation frequency Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000037434 nonsense mutation Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000010442 DNA editing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000991410 Homo sapiens Nucleolar and spindle-associated protein 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102100030991 Nucleolar and spindle-associated protein 1 Human genes 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 102000051625 human USH2A Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
Description
Claims (25)
- 一种基于LEAPER技术靶向编辑细胞中靶标RNA的方法,其中所述靶标RNA为USH2A基因转录本中含有G到A突变的RNA,该方法包括:将包含用于编辑靶标RNA的腺苷脱氨酶招募RNA(arRNA)的构建体或编码所述arRNA的构建体导入所述细胞中,其中所述arRNA包含与所述靶标RNA杂交的互补RNA序列,并且其中所述arRNA能够招募作用于RNA的腺苷脱氨酶(ADAR)以使靶标RNA中的靶标腺苷脱氨基。
- 如权利要求1中所述的方法,其中所述靶标RNA为mRNA前体(Pre-mRNA)。
- 如权利要求1或2中所述的方法,其中所述arRNA长约151-61nt、131-66nt、121-66nt、111-66nt、91-66nt或81-66nt。
- 如权利要求3中所述的方法,其中所述arRNA长度选自66nt-131nt中的任意自然数。
- 如权利要求1-4中任一项所述的方法,其中所述arRNA中靶向碱基距离3’端的长度≥7nt,≥10nt、≥15nt,优选16-55nt、20-50nt、25-45nt、25-35nt或25-30nt。
- 如权利要求1-5中任一项所述的方法,其中所述arRNA中靶向碱基距离5’端的长度≥25nt,≥30、≥35、≥45,优选46-90nt、50-85nt、55-80nt、60-75nt或65-70nt。
- 权利要求1-6中任一项的方法,其中向所述arRNA引入与靶标序列中的靶标A配对的靶向碱基,该靶向碱基的优选次序从高到低依次为C、A、U或G。
- 如权利要求1-7中任一项的方法,其中所述靶标RNA为包含转录有人USH2A基因NM_206933.2(USH2A)_c.11864 G>A(p.Trp3955Ter)突变位点的RNA。
- 如权利要求1-8中任一项所述的方法,其中所述arRNA选自:SEQ ID NO:23、SEQ ID NO:25、SEQ ID NO:26、SEQ ID NO:27、SEQ ID NO:28、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:17、SEQ ID NO:18、SEQ ID NO:19、SEQ ID NO:11、SEQ ID NO:12、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:8、SEQ ID NO:9、SEQ ID NO:2、SEQ ID NO:3或SEQ ID NO:4。
- 如权利要求1-9中任一项所述的方法,其中所述arRNA选自:SEQ ID NO:7、SEQ ID NO:8或SEQ ID NO:9。
- 如权利要求1-10中任一项所述的方法,其中所述构建体为线性核酸、病毒载体、或质粒。
- 如权利要求11中所述的方法,其中所述病毒载体为腺相关病毒(AAV)载体或慢病毒载体。
- 如权利要求12中所述的方法,其中所述AAV载体包装入AAV2、AAV5或AAV8衣壳后通过侵染导入所述细胞中。
- 如权利要求13中所述的方法,所述AAV载体包装入AAV8衣壳后通过侵染导入所述细胞中。
- 如权力要求1-14中任一项所述的方法,其中所述细胞为哺乳动物视神经细胞或听神经细胞。
- 一种用于靶向编辑USH2A基因转录本中含有G到A突变的靶标RNA的arRNA,包含选自如下的序列或由选自如下的序列组成:SEQ ID NO:23、SEQ ID NO:25、SEQ ID NO:26、SEQ ID NO:27、SEQ ID NO:28、SEQ ID NO:29、SEQ ID NO:30、SEQ ID NO:17、SEQ ID NO:18、SEQ ID NO:19、SEQ ID NO:11、SEQ ID NO:12、SEQ ID NO:6、SEQ ID NO:7、SEQ ID NO:8、SEQ ID NO:9、SEQ ID NO:2、SEQ ID NO:3、或SEQ ID NO:4。
- 包含权利要求16的arRNA的构建体或递送体。
- 如权利要求17的构建体或递送体,其为质粒、病毒、脂质体、或脂质纳米颗粒。
- 如权利要求18的构建体或递送体,其为腺相关病毒(AAV)或慢病毒。
- 如权利要求19的构建体或递送体,其所述病毒为AAV2、AAV5或AAV8。
- 通过权利要求1-15中任一项的方法编辑获得的细胞。
- 一种治疗个体中Usher II型综合征的方法,包括使用权利要求1-15 中任一项所述的方法校正所述个体的细胞中与Usher II型综合征有关的G到A的突变。
- 如权利要求22中所述的方法,其包括将如权利要求16中所述的arRNA或如权利要求17-20中任一项所述的构建体或递送体导入受试者。
- 权利要求23的方法,其中将如权利要求16中所述的arRNA或如权利要求17-20中任一项所述的构建体或递送体导入受试者视网膜下腔中。
- 如权利要求16中所述的arRNA或如权利要求17-20中任一项所述的构建体或递送体在制备治疗Usher II型综合征的药物中的用途。
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022540983A JP2023509177A (ja) | 2019-12-30 | 2020-12-30 | Usher症候群を治療する方法及びその組成物 |
AU2020418026A AU2020418026A1 (en) | 2019-12-30 | 2020-12-30 | Method for treating usher syndrome and composition thereof |
IL294260A IL294260A (en) | 2019-12-30 | 2020-12-30 | A method and preparation for the treatment of Asher syndrome |
CA3163280A CA3163280A1 (en) | 2019-12-30 | 2020-12-30 | Method for treating usher syndrome and composition thereof |
EP20909536.3A EP4086346A4 (en) | 2019-12-30 | 2020-12-30 | METHOD FOR TREATMENT OF USHER SYNDROME AND ASSOCIATED COMPOSITION |
MX2022008197A MX2022008197A (es) | 2019-12-30 | 2020-12-30 | Metodo para el tratamiento del sindrome de usher y composicion del mismo. |
US17/790,484 US20230067480A1 (en) | 2019-12-30 | 2020-12-30 | Method for treating usher syndrome and composition thereof |
CR20220366A CR20220366A (es) | 2019-12-30 | 2020-12-30 | Método para el tratamiento del síndrome de usher y composición del mismo |
BR112022012921A BR112022012921A2 (pt) | 2019-12-30 | 2020-12-30 | Métodos para editar de forma alvejada ácido ribonucleico e para tratar a síndrome de usher tipo ii, ácido ribonucleico de recrutamento da adenosina desaminase, construto ou vetor de entrega, célula, e, uso do ácido ribonucleico de recrutamento da adenosina desaminase ou do construto ou vetor de entrega |
CN202080086703.4A CN114829598A (zh) | 2019-12-30 | 2020-12-30 | 一种治疗Usher综合征的方法和其组合物 |
KR1020227024955A KR20220118512A (ko) | 2019-12-30 | 2020-12-30 | 어셔 증후군의 치료 방법 및 그것의 조성물 |
CONC2022/0010430A CO2022010430A2 (es) | 2019-12-30 | 2022-07-26 | Método para el tratamiento del síndrome de usher y composición del mismo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2019129957 | 2019-12-30 | ||
CNPCT/CN2019/129957 | 2019-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021136404A1 true WO2021136404A1 (zh) | 2021-07-08 |
Family
ID=76687119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/141501 WO2021136404A1 (zh) | 2019-12-30 | 2020-12-30 | 一种治疗Usher综合征的方法和其组合物 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230067480A1 (zh) |
EP (1) | EP4086346A4 (zh) |
JP (1) | JP2023509177A (zh) |
KR (1) | KR20220118512A (zh) |
CN (1) | CN114829598A (zh) |
AU (1) | AU2020418026A1 (zh) |
BR (1) | BR112022012921A2 (zh) |
CA (1) | CA3163280A1 (zh) |
CO (1) | CO2022010430A2 (zh) |
CR (1) | CR20220366A (zh) |
EC (1) | ECSP22059858A (zh) |
IL (1) | IL294260A (zh) |
MX (1) | MX2022008197A (zh) |
TW (1) | TW202138561A (zh) |
WO (1) | WO2021136404A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11661596B2 (en) | 2019-07-12 | 2023-05-30 | Peking University | Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs |
US11702658B2 (en) | 2019-04-15 | 2023-07-18 | Edigene Therapeutics (Beijing) Inc. | Methods and compositions for editing RNAs |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024084048A1 (en) | 2022-10-21 | 2024-04-25 | Proqr Therapeutics Ii B.V. | Heteroduplex rna editing oligonucleotide complexes |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD128000A1 (de) | 1976-10-19 | 1977-10-26 | Gerhard Wuerker | Steuereinrichtung fuer einen zwei hauptpumpen besitzenden hydraulischen antrieb |
WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
CN109072239A (zh) * | 2016-04-25 | 2018-12-21 | ProQR治疗上市公司Ⅱ | 治疗眼病的寡核苷酸 |
CN109804069A (zh) * | 2016-09-23 | 2019-05-24 | ProQR治疗上市公司Ⅱ | 治疗眼部疾病的反义寡核苷酸 |
WO2019123429A1 (en) * | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a |
WO2019183641A1 (en) * | 2018-03-23 | 2019-09-26 | Massachusetts Eye And Ear Infirmary | Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome |
WO2020074001A1 (en) | 2018-10-12 | 2020-04-16 | Peking University | Methods and Compositions for Editing RNAs |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021020608A8 (pt) * | 2019-04-15 | 2023-03-21 | Univ Beijing | Rna recrutador de desaminase, construção, método para editar um rna alvo em uma célula hospedeira, e, construção, composição, célula, biblioteca ou kit |
-
2020
- 2020-12-30 KR KR1020227024955A patent/KR20220118512A/ko not_active Application Discontinuation
- 2020-12-30 BR BR112022012921A patent/BR112022012921A2/pt not_active Application Discontinuation
- 2020-12-30 EP EP20909536.3A patent/EP4086346A4/en active Pending
- 2020-12-30 CR CR20220366A patent/CR20220366A/es unknown
- 2020-12-30 MX MX2022008197A patent/MX2022008197A/es unknown
- 2020-12-30 TW TW109146911A patent/TW202138561A/zh unknown
- 2020-12-30 CN CN202080086703.4A patent/CN114829598A/zh active Pending
- 2020-12-30 AU AU2020418026A patent/AU2020418026A1/en active Pending
- 2020-12-30 WO PCT/CN2020/141501 patent/WO2021136404A1/zh unknown
- 2020-12-30 US US17/790,484 patent/US20230067480A1/en active Pending
- 2020-12-30 CA CA3163280A patent/CA3163280A1/en active Pending
- 2020-12-30 IL IL294260A patent/IL294260A/en unknown
- 2020-12-30 JP JP2022540983A patent/JP2023509177A/ja active Pending
-
2022
- 2022-07-26 CO CONC2022/0010430A patent/CO2022010430A2/es unknown
- 2022-07-29 EC ECSENADI202259858A patent/ECSP22059858A/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD128000A1 (de) | 1976-10-19 | 1977-10-26 | Gerhard Wuerker | Steuereinrichtung fuer einen zwei hauptpumpen besitzenden hydraulischen antrieb |
WO2015134812A1 (en) * | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
CN109072239A (zh) * | 2016-04-25 | 2018-12-21 | ProQR治疗上市公司Ⅱ | 治疗眼病的寡核苷酸 |
CN109804069A (zh) * | 2016-09-23 | 2019-05-24 | ProQR治疗上市公司Ⅱ | 治疗眼部疾病的反义寡核苷酸 |
WO2019123429A1 (en) * | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a |
WO2019183641A1 (en) * | 2018-03-23 | 2019-09-26 | Massachusetts Eye And Ear Infirmary | Crispr/cas9-mediated exon-skipping approach for ush2a-associated usher syndrome |
WO2020074001A1 (en) | 2018-10-12 | 2020-04-16 | Peking University | Methods and Compositions for Editing RNAs |
Non-Patent Citations (20)
Title |
---|
AQUINO-JARQUIN GUILLERMO: "Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 19, 1 March 2020 (2020-03-01), US, pages 1065 - 1072, XP055809492, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2019.12.042 * |
BOUGHMAN, J. A.VERNON, M.SHAVER, K. A.: "Usher syndrome: definition and estimate of prevalence from two high-risk populations", JOURNAL OF CHRONIC DISEASES, vol. 36, no. 8, 1983, pages 595 - 603, XP023090260, DOI: 10.1016/0021-9681(83)90147-9 |
CARLA FUSTER-GARCÍA, GARCÍA-GARCÍA GEMA, GONZÁLEZ-ROMERO ELISA, JAIJO TERESA, SEQUEDO MARÍA D., AYUSO CARMEN, VÁZQUEZ-MANRIQUE RAF: "USH2A Gene Editing Using the CRISPR System", MOLECULAR THERAPY-NUCLEIC ACIDS, CELL PRESS, US, vol. 8, 15 September 2017 (2017-09-15), US, pages 529 - 541, XP055572855, ISSN: 2162-2531, DOI: 10.1016/j.omtn.2017.08.003 * |
COX, D. B.GOOTENBERG, J. S.ABUDAYYEH, O. O.FRANKLIN, B.KELLNER, M. J.JOUNG, J.ZHANG, F.: "RNA editing with CRISPR-Casl3", SCIENCE, vol. 358, no. 6366, 2017, pages 1019 - 1027, XP055491658, DOI: 10.1126/science.aaq0180 |
DAVENPORT, S. L. H.OMENN, G. S.: "The heterogeneity of Usher syndrome", INT. CONF. BIRTH DEFECTS, MONTREAL., 1977 |
GR0NDAHL, J.: "Estimation of prognosis and prevalence of retinitis pigmentosa and Usher syndrome in Norway", CLINICAL GENETICS, vol. 31, no. 4, 1987, pages 255 - 264 |
KRAWITZ PETER M., SCHISKA DANIELA, KRÜGER ULRIKE, APPELT SANDRA, HEINRICH VERENA, PARKHOMCHUK DMITRI, TIMMERMANN BERND, MILLAN JOS: "Screening for Single Nucleotide Variants, Small Indels and Exon Deletions with a Next-generation Sequencing Based Gene Panel Approach for Usher Syndrome", MOLECULAR GENETICS & GENOMIC MEDICINE, vol. 2, no. 5, 1 September 2014 (2014-09-01), pages 393 - 401, XP055825979, ISSN: 2324-9269, DOI: 10.1002/mgg3.92 * |
LEWIS E. FRY, PEDDLE CAROLINE F., BARNARD ALUN R., MCCLEMENTS MICHELLE E., MACLAREN ROBERT E.: "RNA Editing as a Therapeutic Approach for Retinal Gene Therapy Requiring Long Coding Sequences", INT. J. MOL. SCI., vol. 21, no. 3, 1 January 2020 (2020-01-01), pages 777, XP055699684, ISSN: 1661-6596, DOI: 10.3390/ijms21030777 * |
LIU, X.BULGAKOV, O. V.DARROW, K. N.PAWLYK, B.ADAMIAN, M.LIBERMAN, M. C.LI, T.: "Usherin is required for maintenance of retinal photoreceptors and normal development of cochlear hair cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 104, no. 11, 2007, pages 4413 - 4418, XP055470637, DOI: 10.1073/pnas.0610950104 |
MERKLE, T.MERZ, S.REAUTSCHNIG, P.BLAHA, A.LI, Q.VOGEL, P.STAFFORST, T.: "Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides", NATURE BIOTECHNOLOGY, vol. 37, no. 2, 2019, pages 133, XP036900581, DOI: 10.1038/s41587-019-0013-6 |
NEUHAUS, C.EISENBERGER, T.DECKER, C.NAGL, S.BLANK, C.PFISTER, M.BECK, B.: "Next-generation sequencing reveals the mutational landscape of clinically diagnosed Usher syndrome: copy number variations, phenocopies, a predominant target for translational read-through, and PEX 26 mutated in Heimler syndrome", MOLECULAR GENETICS & GENOMIC MEDICINE, vol. 5, no. 5, 2017, pages 531 - 552 |
OTTERSTEDDE, C. R.SPANDAU, U.BLANKENAGEL, A.KIMBERLING, W. J.REISSER, C.: "A new clinical classification for Usher's syndrome based on a new subtype of Usher's syndrome type I", THE LARYNGOSCOPE, vol. 111, no. 1, 2001, pages 84 - 86 |
POLLARD, K. M.CAUVI, D. M.TOOMEY, C. B.MORRIS, K. V.KONO, D. H.: "Interferon-y and systemic autoimmunity", DISCOVERY MEDICINE, vol. 16, no. 87, 2013, pages 123 |
PROFESSOR WEI WENSHENG: "Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs", NATURE BIOTECHNOLOGY, July 2019 (2019-07-01) |
QU LIANG, YI ZONGYI, ZHU SHIYOU, WANG CHUNHUI, CAO ZHONGZHENG, ZHOU ZHUO, YUAN PENGFEI, YU YING, TIAN FENG, LIU ZHIHENG, BAO YING,: "Leveraging Endogenous ADAR for Programmable Editing on RNA", BIORXIV, 19 April 2019 (2019-04-19), XP055825931, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/605972v1.full.pdf> DOI: 10.1101/605972 * |
QU LIANG; YI ZONGYI; ZHU SHIYOU; WANG CHUNHUI; CAO ZHONGZHENG; ZHOU ZHUO; YUAN PENGFEI; YU YING; TIAN FENG; LIU ZHIHENG; BAO YING;: "Author Correction: Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs", NATURE BIOTECHNOLOGY, GALE GROUP INC., NEW YORK, vol. 37, no. 11, 25 September 2019 (2019-09-25), New York, pages 1380 - 1380, XP036920810, ISSN: 1087-0156, DOI: 10.1038/s41587-019-0292-y * |
QU, L.YI, Z.ZHU, S.WANG, C.CAO, Z.ZHOU, Z.BAO, Y.: "Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs", NATURE BIOTECHNOLOGY, vol. 37, no. 9, 2019, pages 1059 - 1069, XP036888288, DOI: 10.1038/s41587-019-0178-z |
See also references of EP4086346A4 |
USHER, C. H.: "On the inheritance of retinitis pigmentosa; with note of cases", ROYAL LONDON OP HALMOL HOSP REP, vol. 19, 1914, pages 130 - 236 |
XU, L.WANG, J.LIU, Y.XIE, L.SU, B.MOU, D.ZHAO, L.: "CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia", NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 13, 2019, pages 1240 - 1247 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11702658B2 (en) | 2019-04-15 | 2023-07-18 | Edigene Therapeutics (Beijing) Inc. | Methods and compositions for editing RNAs |
US11661596B2 (en) | 2019-07-12 | 2023-05-30 | Peking University | Targeted RNA editing by leveraging endogenous ADAR using engineered RNAs |
US11827880B2 (en) | 2019-12-02 | 2023-11-28 | Shape Therapeutics Inc. | Therapeutic editing |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024084048A1 (en) | 2022-10-21 | 2024-04-25 | Proqr Therapeutics Ii B.V. | Heteroduplex rna editing oligonucleotide complexes |
Also Published As
Publication number | Publication date |
---|---|
JP2023509177A (ja) | 2023-03-07 |
CN114829598A (zh) | 2022-07-29 |
US20230067480A1 (en) | 2023-03-02 |
BR112022012921A2 (pt) | 2022-09-06 |
AU2020418026A1 (en) | 2022-08-18 |
EP4086346A1 (en) | 2022-11-09 |
TW202138561A (zh) | 2021-10-16 |
EP4086346A4 (en) | 2024-03-20 |
MX2022008197A (es) | 2022-08-02 |
CR20220366A (es) | 2022-11-28 |
IL294260A (en) | 2022-08-01 |
CO2022010430A2 (es) | 2022-08-09 |
CA3163280A1 (en) | 2021-07-08 |
KR20220118512A (ko) | 2022-08-25 |
ECSP22059858A (es) | 2022-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021136404A1 (zh) | 一种治疗Usher综合征的方法和其组合物 | |
US20230233651A1 (en) | Materials and methods for treatment of titin-based myopathies and other titinopathies | |
EP4015633A1 (en) | Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases | |
JP6775584B2 (ja) | 設計されたメガヌクレアーゼを使用した網膜色素変性症の治療 | |
WO2021136408A1 (zh) | 一种基于leaper技术治疗mps ih的方法和组合物 | |
CN112662674B (zh) | 靶向编辑VEGFA基因外显子区域的gRNA及其应用 | |
JP7272795B2 (ja) | 優性網膜色素変性の治療のためのaavベクター | |
Mohanna et al. | LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea | |
WO2023207672A1 (zh) | Rs1基因在制备xlrs治疗剂中的应用及治疗剂 | |
WO2018021855A1 (ko) | Cas9 단백질 및 가이드 RNA를 포함하는 안질환 치료용 약학 조성물 | |
Kumar et al. | RNA-targeting strategies as a platform for ocular gene therapy | |
US20230075045A1 (en) | Engineered crispr/cas13 system and uses thereof | |
Yan et al. | Genome editing, a superior therapy for inherited retinal diseases | |
Sundaresan et al. | Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases | |
WO2022167009A1 (zh) | 靶向Aqp1 mRNA的sgRNA及其载体与应用 | |
JP7393770B2 (ja) | ゲノム編集による2つの最も高頻度に見られるush2a突然変異の修正 | |
WO2021212686A1 (zh) | RHO-adRP基于基因编辑的方法和组合物 | |
WO2024088175A1 (zh) | 基因编辑系统及其应用 | |
EP2872635A2 (en) | Genome surgery with paired, permeant endonuclease excision | |
TW201918556A (zh) | 用於細胞重編程之方法及組合物 | |
Naser et al. | Ocular Gene Therapy | |
WO2023143538A1 (zh) | 基于leaper技术治疗mpsi的方法和组合物 | |
Hassall et al. | Retinal Gene Therapy | |
CN116334141A (zh) | 基于基因编辑的RHO-R135W-adRP基因编辑药物 | |
Jaskula-Ranga | 23 Genome Editing for Retinal Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20909536 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3163280 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022540983 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022012921 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20227024955 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020418026 Country of ref document: AU Date of ref document: 20201230 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020909536 Country of ref document: EP Effective date: 20220801 |
|
ENP | Entry into the national phase |
Ref document number: 112022012921 Country of ref document: BR Kind code of ref document: A2 Effective date: 20220628 |